anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Assess the adequacy of therapy by periodic assessment of laboratory tests and clinical evaluation. Persistent clinical and laboratory evidence of hypothyroidism despite an apparent adequate replacement dose of levothyroxine sodium tablets may be evidence of inadequate absorption, poor compliance, drug interactions, or a combination of these factors.

Biotin supplementation may interfere with immunoassays for TSH, T4, and T3, resulting in erroneous thyroid hormone test results. Stop biotin and biotin-containing supplements for at least 2 days before assessing TSH and/or T4 levels [see Drug Interactions (7.10)].

Adults

In adult patients with primary hypothyroidism, monitor serum TSH levels after an interval of 6 to 8 weeks after any change in dosage. In patients on a stable and appropriate replacement dosage, evaluate clinical and biochemical response every 6 to 12 months and whenever there is a change in the patient’s clinical status.

Pediatric Patients

In patients with hypothyroidism, assess the adequacy of replacement therapy by measuring both serum TSH and total or free-T4. Monitor TSH and total or free-T4 in pediatric patients as follows: 2 and 4 weeks after the initiation of treatment, 2 weeks after any change in dosage, and then every 3 to 12 months thereafter following dosage stabilization until growth is completed. Poor compliance or abnormal values may necessitate more frequent monitoring. Perform routine clinical examination, including assessment of development, mental and physical growth, and bone maturation, at regular intervals.

The general aim of therapy is to normalize the serum TSH level. TSH may not normalize in some patients due to in utero hypothyroidism causing a resetting of pituitary-thyroid feedback. Failure of the serum T4 to increase into the upper half of the normal range within 2 weeks of initiation of levothyroxine sodium tablet therapy and/or of the serum TSH to decrease below 20 mIU per liter within 4 weeks may indicate the patient is not receiving adequate therapy. Assess compliance, dose of medication administered, and method of administration prior to increasing the dose of levothyroxine sodium tablets [see Warnings and Precautions (Error! Hyperlink reference not valid.) and Use in Specific Populations (Error! Hyperlink reference not valid.)].

Secondary and Tertiary Hypothyroidism

Monitor serum free-T4 levels and maintain in the upper half of the normal range in these patients.
Brodalumab is an anti-IL-17 receptor antibody and blocks the inflammatory effects of IL-17 in the skin. Some psoriasis patients with a higher body weight experienced a lower treatment effect of brodalumab in clinical studies. Therefore, the purpose of this study is to investigate if increasing the dose of brodalumab will increase the effect of treatment for patients with a higher body weight. The study will run over 60-62 weeks, including screening, treatment period and safety follow-up, with the primary endpoint measurement at Week 40. Patients will receive subcutaneous injections of brodalumab at Week 0, 1, and 2, followed by injections every 2 weeks. Participants not fulfilling a predefined response at any time after Week 16 will receive a dose adjustment to 280 mg brodalumab or 210 mg brodalumab plus placebo every 2 weeks.
The present invention relates to a method for obtaining an agent with antitumor activity from a BCG vaccine, to an agent with antitumor activity based on a BCG vaccine, and to its use as a means for the prevention and treatment of cancer diseases. The method according to this invention provides for the production of medications with different potencies of impact which enables their adequate dosing. The agent obtained according to the method exhibits reduced toxicity due to the low content of live bacteria, and a higher curative effect than the known agents. In the present invention the problem is resolved by a method for obtaining the agent by mixing three fractions: fraction 1 containing live Mycobacterium bovis bacteria from BCG vaccine; fraction 2 representing a suspension of inactivated Mycobacterium bovis bacteria from BCG vaccine, and fraction 3 representing the filtrate of a suspension of ultrasonically destroyed Mycobacterium bovis bacteria from BCG vaccine in quantities such that the ratio between the three fractions is 1:10:100 units by volume. The method results in the production of an antitumor agent consisting of fraction 1 which comprises live Mycobacterium bovis bacteria, fraction 2 which comprises a suspension of inactivated Mycobacterium bovis bacteria, and fraction 3 which comprises the filtrate of a suspension of ultrasonically destroyed Mycobacterium bovis bacteria cells in ratio 1:10:100 by volume. In addition to live bacteria, the agent contains killed bacteria and bacterial parts, bacteria cell walls, inner cytoplasmic membrane, enzymes, ribosomes, bacterial nuclei, wax, proteins, carbohydrates, lipids and nucleic acids. The agent obtained by this method is intended for the treatment of oncological diseases affecting various organs and systems in the human body. It is particularly suitable for preventing the onset of oncological diseases in individuals at risks as well as for the prevention of recurrences.
Spit tobacco presents as many health risks to its users as smoking tobacco. It affects the cardiovascular system and may be associated with heart disease, stroke, and high blood pressure. Long-term effects of spit tobacco use include tooth abrasion, gum recession, mouth disease, bone loss in the jaw, yellowing of the teeth, and chronic bad breath. Although a significant number of ST users recognize the importance of quitting, many either do not want to quit or feel it is impossible. For these individuals, tobacco reduction may be an important transitional goal, either prior to quitting, or as a treatment endpoint; however, approaches to help ST users reach this goal have not been studied. This study will assess the effectiveness of limiting ST nicotine intake in reducing levels of exposure to tobacco and associated toxicity, as well as enhancing motivation to either quit or sustain lower levels of nicotine intake.

Participants in this open-label study will be randomly assigned to one of three treatment conditions: switching to an ST brand with less concentrated nicotine and controlling for ST use; switching to an ST brand with less concentrated nicotine, combined with no limit on ST intake; or continued use of usual ST brand with no limit on intake (control group). Participants in both brand-switching conditions will use ST brands that have 50% less nicotine than their usual ST brands for the first 4 weeks. For the next 4 weeks, participants in the brand-switching conditions will use ST brands that have 75% less nicotine that their usual ST brands. Study visits will ocur once weekly during the 8-week treatment period. The number of participants who do not complete treatment, reduce nicotine intake, or quit completely will be assessed at Week 8 and at follow-up visits, which will be held 12 and 26 weeks following the completion of treatment.
Lymph node status is a key factor in determining stage, treatment, and prognosis in cancers. Small lymph nodes in fat-rich gastrointestinal and breast cancer specimens are easily missed in conventional sampling methods. This study examined the effectiveness of the degreasing pretreatment with dimethyl sulfoxide (DMSO) in lymph node detection and its impact on the analysis of clinical treatment-related proteins and molecules. Thirty-three cases of gastrointestinal cancer specimens from radical gastrectomy and 63 cases of breast cancer specimens from modified radical mastectomy were included. After routine sampling of lymph nodes, the specimens were immersed in DMSO for 30 minutes for defatting. We assessed changes in the number of detected lymph nodes and pN staging in 33 gastrointestinal cancer specimens and 37 breast cancer specimens. In addition, we analyzed histologic characteristics, Masson trichrome special staining, and immunohistochemistry (gastrointestinal cancer: MMR, HER2, and PD-L1; breast cancer: ER, PR, AR, HER2, Ki-67, and PD-L1). Molecular status was evaluated for colorectal cancer (KRAS, NRAS, BRAF, and microsatellite instability) and breast cancer (HER2) in gastrointestinal cancer specimens and the remaining 26 breast cancer specimens. Compared with conventional sampling, DMSO pretreatment increased the detection rate of small lymph nodes (gastrointestinal cancer: P < .001; breast cancer: P < .001) and improved pN staging in 1 case each of gastric cancer, colon cancer, and rectal cancer (3/33; 9.1%). No significant difference in the morphology, special staining, protein, and molecular status of cancer tissue after DMSO treatment was found. Based on these results and our institutional experience, we recommend incorporating DMSO degreasing pretreatment into clinical pathologic sampling practices.
Adjuvant chemotherapy for patients with completely resected stage II and select stage III NSCLC is considered standard therapy. At least three large, prospective randomized trials have proven the benefit of adjuvant chemotherapy in improving survival in these patients (with a magnitude of benefit ranging from 4-12%). However, in patients who are not considered to be candidates for up-front complete resection, preoperative therapy may be indicated. Many of these patients will subsequently be eligible for resection (bimodality therapy). The rationale for this multicenter, Phase II trial is to examine the impact of carboplatin/paclitaxel with bevacizumab in the preoperative treatment of patients with stage IB (\>4.0 cm), II, and select stage III NSCLC. This trial will be conducted by the Sarah Cannon Research Institute Oncology Research Consortium. If this novel regimen proves to be safe and active in this setting, this would provide rationale for further investigation in a larger, prospective, randomized setting.
Chikungunya virus (CHIKV) is a mosquito-borne alphavirus causing a debilitating febrile illness with rheumatic disease symptoms of arthralgia and arthritis. Since its spread outside of Africa in 2005, it continues to cause outbreaks and disseminates into new territories. Intervention strategies are urgently required, including vaccination and antiviral approaches. To test efficacy, the use of small animal models is required. Two mouse strains, A129, with a deficiency in their type-I interferon (IFN) receptor, and C57BL/6 are widely used. A direct comparison of these strains alongside the wild-type parental strain of the A129 mice, 129Sv/Ev, was undertaken to assess clinical disease progression, viral loads in key tissues, histological changes and levels of sera biomarkers. Our results confirm the severe disease course in A129 mice which was not observed in the parental 129Sv/Ev strain. Of the two wild-type strains, viral loads were higher in 129Sv/Ev mice compared to C57BL/6 counterparts. Our results have established these models and parameters for the future testing of vaccines and antiviral approaches.
PCT No. PCT/US94/13394 Sec. 371 Date May 17, 1995 Sec. 102(e) Date May 17, 1995 PCT Filed Nov. 16, 1994 PCT Pub. No. WO95/14037 PCT Pub. Date May 26, 1995There is provided a stable transparent multi-component composition useful for the delivery of water soluble active agents to animals. The compositions are formulated with a mixture of an oil phase, an aqueous phase, and a surfactant system, along with the active agent to be delivered to the animal. The compositions are specially formulated to be compatible with capsules such as gelatin and starch capsules. The aqueous phase of the compositions contains a substantial amount of polyethylene glycol and can optionally also contain a plasticizer. Preferred active agents are proteinaceous materials.
The multiple fetal heart sound detecting system includes detecting modules, a portable electronic device and a database. The detecting collection module acquires fetal heart sound signals from different fetuses. The portable electronic device is to receive the fetal heart sound signals and includes a multi-fetal heart sound recording module, a multi-fetal heart sound setting module, a multi-fetal heart sound searching module, and a multi-fetal heart sound history module. The multi-fetal heart sound recording module is to record the fetal heart sound signals from different infants. The multi-fetal heart sound setting module is to set the received fetal heart sound signals. The multi-fetal heart sound searching module is to query the fetal heart sound signal at a specific time period, and the multi-fetal heart sound history module is to show fetal heart sound signals at multiple time points. The database receives and stores multiple fetal heart sound signals from the portable electronic device.
The present disclosure relates to determining domain names of a group entity using electronic activities and systems of record. A method can include maintaining a plurality of node profiles including one or more node field-value pairs. Each node profile of the plurality of node profiles can identify a group entity. The method can include identifying a first domain name corresponding to the group entity. The method can include accessing a plurality of data points corresponding to a subset of the plurality of node profiles. The method can include updating each respective node profile of the subset to include a respective second electronic account identifier corresponding to the node profile. The method can include storing, in at least one first data structure, an association between the group entity, the first domain name, and a second domain name corresponding to the second electronic account identifiers.
Participants participate in virtual exercise classes at least TIW over 20-60 minutes for 12 weeks. Participants are expected to work towards achieving the national physical activity exercise guidelines of 150 minutes of moderate intensity aerobic based physical activity and 2-3 strength training sessions each week.
Participants will receive 4 weekly individual sessions of IR, at the end of which, a chosen odor will be presented while imagining the positive imagery generated during IR. During 4 weeks, patients of this group will practice IR at home every day in bed and have the same odor being diffused during the night.
Participants randomized to this arm will consume 5 servings/day of Bariatrics Advantage meal replacement in conjunction of 400 kcal of solid food for 12 weeks during the weight loss portion of the trial. This will be followed by the consumption of 1 serving/day of Bariatrics Advantage meal replacement for 12 weeks during the weight maintenance portion of the trial.
The invention relates to the G protein-coupled EDG6 receptor, fragments, variants and mutations thereof, as well as to its use. Areas of application of the invention include molecular biology, pharmacy and medicine. The aim of the invention is to isolate and identify a further member of the family of EDG receptors and to permit its use for medical purposes. The new human EDG6 receptor comprises 384 amino acids of sequence 1 having seven transmembrane domains. The receptor has a possible N-terminal glycolysis site, three possible palmitoylation sites, between 12 and 15 amino acids in the C-terminal position of the seventh transmembrane domain and four possible C-terminal proteinkinase C-phosphorylation sites. The invention further relates to the use of the EDG6 receptor, its fragments, variants and mutations and possibly its binding partners for therapeutic methods and treatments.
PROBLEM TO BE SOLVED: To efficiently collect a large amount of the subject precipitate while carrying out devising countermeasures such as inhibition of proliferation of bacteria, prevention of hemolysis, prevention of decline of physiologically active substance, etc., by mixing a mammal blood with a solution of an anticoagulant to form a starting substance and subjecting the substance to plural specific processes. SOLUTION: (A) Mammal blood is mixed with (B) an anticoagulant to form (C) a starting substance. The component C is put in a collecting means while keeping it a fixed low-temperature state and a material component is removed. (D) Blood containing the objective substance is collected, the component D is put in a cooling tank, mixed with (E) a fixed amount of a substance for precipitation reaction and (F) a precipitate is separated from (G) a supernatant liquid. The component F is removed by the collecting means. On the other hand, the component G is collected, the component G is put in a cooling tank, mixed with a fixed amount of (H) a substance for a precipitation reaction, (I) a precipitate containing an active ingredient is separated from (J) a supernatant liquid and the component J is removed by the collecting means. The component I is collected to give the objective precipitate.
Patients should be made aware of the possibility of syncopal and orthostatic symptoms, especially at the initiation of therapy, and to avoid driving or hazardous tasks for 12 hours after the first dose, after a dosage increase and after interruption of therapy when treatment is resumed. They should be cautioned to avoid situations where injury could result should syncope occur during initiation of terazosin therapy. They should also be advised of the need to sit or lie down when symptoms of lowered blood pressure occur, although these symptoms are not always orthostatic, and to be careful when rising from a sitting or lying position. If dizziness, lightheadedness, or palpitations are bothersome they should be reported to the physician, so that dose adjustment can be considered. 

Patients should also be told that drowsiness or somnolence can occur with terazosin, requiring caution in people who must drive or operate heavy machinery. 

Patients should be advised about the possibility of priapism as a result of treatment with Terazosin Capsules and other similar medications. Patients should know that this reaction to Terazosin Capsules is extremely rare, but that if it is not brought to immediate medical attention, it can lead to permanent erectile dysfunction (impotence).
The invention belongs to the field of medicines, especially relates to the field of decitabine preparation, and more especially relates to a decitabine composition, a preparation method of the decitabine composition, an application thereof in a medicinal lyophilized preparation, a medicinal lyophilized preparation product, and a preparation method of the medicinal lyophilized preparation product. The invention aims at providing a decitabine composition and a preparation method thereof. With the decitabine composition, the dissolving speed of decitabine in a preparation process is increased, the stability of a decitabine preparation product is improved, and no organic solvent residue is left in the preparation product. According to the invention, micronized decitabine is adopted as a raw material, and potassium dihydrogen phosphate and sodium hydroxide are adopted as auxiliary materials. With an ultrasonic material dissolving method, the main medicine is dissolved into an emulsion, such that the use of the organic solvent is avoided, and the residue of the organic solvent in the medicine preparation product is avoided. Therefore, the safety of the preparation in clinical application is greatly improved. Also, during a lyophilized preparation production process, lyophilization equipment is prevented from being damaged by the organic solvent.
BACKGROUND: Unplanned vascular admissions have a high mortality. Previous studies have indicated that end of life care (EoLC) among this group of patients is low but there exist limited data on EoLC in the United Kingdom. The aim of this study was to evaluate the quality and predictors of EoLC for unplanned vascular admissions to a tertiary center in the United Kingdom.
METHODS: This was a retrospective single-center cohort study of unplanned vascular surgery admissions from August 1, 2019 to January 22, 2020. Data on patient demographics, markers of quality of palliative care, mortality, and cause of death of unplanned admission to the vascular surgery department were collected from hospital and general practitioner records and evaluated against EoLC to evaluate predictors and efficacy of EoLC. Quality of palliative care markers included documentation of preferred place of death and care priorities, time spent in hospital and the intensive care unit toward the end of life, and realization of documented care objectives. EoLC input was defined as a dedicated palliative care consultation (PCC) by a palliative care professional, medical doctor, surgeon, or advanced care practitioner. We also conducted a subgroup analysis of patients within this group with chronic limb-threatening ischemia (CLTI), diabetic foot, and ruptured aortic aneurysms, as all patients in this group should be offered EoLC according to international guidelines.
RESULTS: One-hundred and fifty patients were included. Median age at presentation was 70.5 years, and the cohort consisted of mostly men (72%). CLTI (31%) was the most common reason for admission. Surgical intervention was carried out in 60% of patients. Two-year mortality was 36%, and pneumonia (22%) was the most common cause of death. Seven percent of patients received PCC, which occurred a median of 10 days before death. Only a minority of patients had preferred place of care/death (14%), care priorities (37%), and family involvement during advance care planning (17%) documented in their notes; 29% of patients had Recommended Summary Plan for Emergency Care and Treatment forms in place. A diagnosis of left ventricular systolic dysfunction, chronic kidney disease, and increasing age predicted Recommended Summary Plan for Emergency Care and Treatment form completion. Patients with PCC were more likely to have advance care planning, but this did not translate into improvements in the other markers of quality of palliative and, consequently, EoLC.
CONCLUSIONS: EoLC was insufficient and of low quality despite a high mortality in this group. Clinical guidelines and pathways are needed to ensure these patients are considered for EoLC and those with CLTI, diabetic foot sepsis or ruptured abdominal aortic aneurysms are offered it by default. Further research is needed to help identify vascular patients who would benefit from EoLC earlier to improve quality at end of life.
Patients undergo TCD examination including bilateral evaluation of standard intracranial arterial segments including the M1 and M2 segments of the MCA, the ACA and PCA, via the transtemporal acoustic windows, the ICA siphon via transorbital approach, and the vertebral and basilar arteries (proximal, mid, and distal) via the suboccipital approach. Patients also undergo MRI. All tests occur between 21 days after completion of surgery and up to 30 days prior to adjuvant chemotherapy and between 20-60 days after completion of adjuvant chemotherapy.
In various embodiments, a personal health data hub (“PHDH”) may include a device that receives health data from personal health devices (“PHDs”), stores the health data, and sends them to personal health records. Health data may be received by PHDH using multiple communication technologies, such as Bluetooth, Bluetooth Low Energy, ANT+, USB, etc. The PHDH may be used by different users such as multiple user sessions. Users may access and control the PHDH through different UI mechanisms. The PHDH may interact with users, such as by indicating states and/or events using light and/or sound indicators. The PHDH may use a wireless collector accessory enabled peripheral device to receive health data from a PHD. The WCA-enabled device may communicate personal health data to the PHDH on behalf of the PHD. Other embodiments are described and claimed.